Market capitalization | $1.45m |
Enterprise Value | $-7.98m |
P/E (TTM) P/E ratio | 0.19 |
EV/FCF (TTM) EV/FCF | 4.11 |
EV/Sales (TTM) EV/Sales | -4.13 |
P/S ratio (TTM) P/S ratio | 0.75 |
P/B ratio (TTM) P/B ratio | 0.07 |
Revenue growth (TTM) Revenue growth | -2.19% |
Revenue (TTM) Revenue | $1.93m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Mar '24 |
+/-
%
|
||
Revenue | 1.93 1.93 |
2%
2%
|
|
Gross Profit | 0.45 0.45 |
5%
5%
|
|
EBITDA | -8.88 -8.88 |
66%
66%
|
EBIT (Operating Income) EBIT | -9.08 -9.08 |
62%
62%
|
Net Profit | -3.10 -3.10 |
48%
48%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
China Sxt Pharmaceuticals, Inc. is a holding company, which engages in the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces (TCMP). Its product categories includes directly-oral, after-soaking-oral, fine, and regular TCMP. It distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.
Head office | Virgin Islands, British |
CEO | Feng Zhou |
Employees | 75 |
Founded | 2005 |
Website | www.sxtchina.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.